Business
WILLOW BIOSCIENCES PUBLISHES THE FIRST PEER REVIEWED ARTICLE DEMONSTRATING THE CLINICAL BENEFIT OF CBG FOR SKINCARE
WILLOW BIOSCIENCES PUBLISHES THE FIRST PEER REVIEWED ARTICLE DEMONSTRATING THE CLINICAL B...
About this update from Atlas Energy Corp.
[{"type":"text","content":"\n \n \n \n WILLOW BIOSCIENCES PUBLISHES THE FIRST PEER REVIEWED ARTICLE DEMONSTRATING THE CLINICAL BENEFIT OF CBG FOR SKINCARE\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n \n \n \n \n \n \n Canada NewsWire\n \n \n \n \n \n VANCOUVER, BC\n \n ,\n \n Jan. 19, 2022\n \n /CNW/ - Willow Biosciences Inc. (\"\n \n Willow\n \n \" or the \"\n \n Company\n \n \") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company that manufactures pure, consistent and sustainable cannabinoids\n \n via\n \n yeast biosynthesis, is pleased to announce the results of its\n \n in vitro\n \n analysis and the first to be reported topical clinical study on cannabigerol (\"\n \n CBG\n \n \"). In collaboration with Signum Biosciences, Willow's FutureGrown\n \n TM\n \n CBG, produced using its proprietary yeast platform at multi-kilogram scale, demonstrated antioxidant, anti-inflammatory, and skin health-boosting activity in lab assays, and provided similar benefits when applied topically to human skin. A single-blind clinical study in 20 healthy male and female volunteers conducted at Princeton Consumer Research (the \"\n \n Willow Study\n \n \") showed Willow's FutureGrown\n \n TM\n \n CBG clinically reduces skin inflammation, the appearance of redness, and improves barrier function. The results of the Willow Study were published in\n \n Molecules\n \n , a leading international, peer-reviewed, open access journal that can be found here at\n \n \n https://www.mdpi.com/1420-3049/27/2/491/htm\n \n \n .\n \n \n \n \n \n \n \n \n \n \"Willow's FutureGrown\n \n TM\n \n CBG continues to exhibit great promise as an exciting new skincare ingredient\", said\n \n Trevor Peters\n \n , Willow's President and Chief Executive Officer. \"We are excited to share the results of our\n \n in vitro\n \n and clinical work with our stakeholders and proud to have it published in a peer reviewed scientific journal, the first of its kind for CBG. As the market for CBG and CBGA continues to develop, key studies such as this help to define the potential these ingredients have in the health and wellness space.\"\n...